The goal of this observational study is to establish a digital diagnosis and treatment system for sarcopenia, integrating research outcomes into a unified approach encompassing a digital vaccine (early warning screening model), digital drug (intervention model associated with pathogenesis), and digital rehabilitation (preventive system combining early warning and treatment). This aims to create a digital visual tertiary prevention network for sarcopenia.

Research aims:

Evaluate the effectiveness of the digital vaccine through a cross-sectional epidemiological survey.

Establish a specialized cohort for sarcopenia through a longitudinal investigation, implementing the digital drug and digital rehabilitation interventions.

Participants will:

Engage in screening and assessment based on inclusion and exclusion criteria.

Be monitored longitudinally, with tailored interventions for those with muscle atrophy and regular follow-ups for at-risk individuals.

Key outcomes will focus on sarcopenia indicators, serum biomarkers, and clinical endpoints such as fracture rates, weakness classification, and quality of life.

Inclusion Criteria:

• Age ≥45 years;
• meeting sarcopenia diagnostic criteria;
• consent to participate in this study

Exclusion Criteria:

• Age <45 years;
• patients in acute phase of chronic illness;
• infectious disease patients;
• people who lack of independent mobility;
• people who lack of communication or cognitive skills;
• people who refusal to participate in this study

outpatient patients, inpatients, elderly population in elderly care institutions, and community registered elderly patients in the north part of China